Gary JD - Corcept Therapeutics Chief Secretary
| CORT Stock | USD 58.60 0.02 0.03% |
Executive
Gary JD is Chief Secretary of Corcept Therapeutics Incorporated
| Age | 61 |
| Address | 149 Commonwealth Drive, Menlo Park, CA, United States, 94025 |
| Phone | 650 327 3270 |
| Web | https://www.corcept.com |
Corcept Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.13 % which means that it generated a profit of $0.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2577 %, meaning that it created $0.2577 on every $100 dollars invested by stockholders. Corcept Therapeutics' management efficiency ratios could be used to measure how well Corcept Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024. Return On Capital Employed is likely to gain to 0.22 in 2024. At this time, Corcept Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 652.6 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 349.7 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lora Pike | Sensei Biotherapeutics | N/A | |
| Michael LaBarre | Halozyme Therapeutics | 60 | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| MS CPA | Erasca Inc | 57 | |
| YulyMae DiNapoli | Cytokinetics | N/A | |
| Tim Randall | MeiraGTx Holdings PLC | N/A | |
| Andres CPA | Ideaya Biosciences | 38 | |
| Mark Esq | Halozyme Therapeutics | N/A | |
| Sarah MD | Agios Pharm | 44 | |
| Diane Weiser | Cytokinetics | N/A | |
| John JD | Edgewise Therapeutics | 60 | |
| Steven CPA | NextCure | 61 | |
| Priya Raina | AnaptysBio | N/A | |
| Stuart Naylor | MeiraGTx Holdings PLC | 61 | |
| Amy Reilly | Dyne Therapeutics | 50 | |
| Nicole MBA | Insmed Inc | 56 | |
| Ashish MBA | Dyne Therapeutics | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| John MBA | Dyne Therapeutics | 61 | |
| Esq JD | Erasca Inc | 52 | |
| Alastair Leighton | MeiraGTx Holdings PLC | N/A | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 |
Corcept Therapeutics Leadership Team
Elected by the shareholders, the Corcept Therapeutics' board of directors comprises two types of representatives: Corcept Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corcept. The board's role is to monitor Corcept Therapeutics' management team and ensure that shareholders' interests are well served. Corcept Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corcept Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hazel Hunt, Chief Officer | ||
| Amy Flood, Chief Officer | ||
| Joseph MD, President, CoFounder | ||
| William PharmD, Chief Officer | ||
| Roberto Vieira, President Oncology | ||
| Gary JD, Chief Secretary | ||
| Gary Robb, CFO, Chief Accounting Officer and Secretary | ||
| Joseph Lyon, Chief Officer | ||
| Monica Tellado, President Markets | ||
| Atabak Mokari, CFO Treasurer | ||
| Sean Maduck, Senior Vice President - Commercial |
Corcept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corcept Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 5.77 B | ||||
| Shares Outstanding | 104.78 M | ||||
| Shares Owned By Insiders | 11.50 % | ||||
| Shares Owned By Institutions | 85.50 % | ||||
| Number Of Shares Shorted | 18.34 M | ||||
| Price To Earning | 30.07 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.